These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 37989747)

  • 1. SETD2 deficiency accelerates sphingomyelin accumulation and promotes the development of renal cancer.
    Rao H; Liu C; Wang A; Ma C; Xu Y; Ye T; Su W; Zhou P; Gao WQ; Li L; Ding X
    Nat Commun; 2023 Nov; 14(1):7572. PubMed ID: 37989747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multilevel Regulation of β-Catenin Activity by SETD2 Suppresses the Transition from Polycystic Kidney Disease to Clear Cell Renal Cell Carcinoma.
    Rao H; Li X; Liu M; Liu J; Feng W; Tang H; Xu J; Gao WQ; Li L
    Cancer Res; 2021 Jul; 81(13):3554-3567. PubMed ID: 33910928
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Functional Studies on Primary Tubular Epithelial Cells Indicate a Tumor Suppressor Role of SETD2 in Clear Cell Renal Cell Carcinoma.
    Li J; Kluiver J; Osinga J; Westers H; van Werkhoven MB; Seelen MA; Sijmons RH; van den Berg A; Kok K
    Neoplasia; 2016 Jun; 18(6):339-46. PubMed ID: 27292023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. miR-106b-5p targets tumor suppressor gene SETD2 to inactive its function in clear cell renal cell carcinoma.
    Xiang W; He J; Huang C; Chen L; Tao D; Wu X; Wang M; Luo G; Xiao X; Zeng F; Jiang G
    Oncotarget; 2015 Feb; 6(6):4066-79. PubMed ID: 25714014
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PI3Kβ inhibitor TGX221 selectively inhibits renal cell carcinoma cells with both VHL and SETD2 mutations and links multiple pathways.
    Feng C; Sun Y; Ding G; Wu Z; Jiang H; Wang L; Ding Q; Wen H
    Sci Rep; 2015 Apr; 5():9465. PubMed ID: 25853938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-resolution profiling of histone h3 lysine 36 trimethylation in metastatic renal cell carcinoma.
    Ho TH; Park IY; Zhao H; Tong P; Champion MD; Yan H; Monzon FA; Hoang A; Tamboli P; Parker AS; Joseph RW; Qiao W; Dykema K; Tannir NM; Castle EP; Nunez-Nateras R; Teh BT; Wang J; Walker CL; Hung MC; Jonasch E
    Oncogene; 2016 Mar; 35(12):1565-74. PubMed ID: 26073078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integrated Genomic and Proteomic Analyses Reveal Novel Mechanisms of the Methyltransferase SETD2 in Renal Cell Carcinoma Development.
    Li L; Miao W; Huang M; Williams P; Wang Y
    Mol Cell Proteomics; 2019 Mar; 18(3):437-447. PubMed ID: 30487242
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Morphological characteristics of SETD2-mutated locally advanced clear cell renal cell carcinoma: Comparison with BAP1-mutated clear cell renal cell carcinoma.
    Takeda K; Bastacky S; Dhir R; Mohebnasab M; Quiroga-Garza GM
    Ann Diagn Pathol; 2024 Feb; 68():152223. PubMed ID: 37976977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adverse outcomes in clear cell renal cell carcinoma with mutations of 3p21 epigenetic regulators BAP1 and SETD2: a report by MSKCC and the KIRC TCGA research network.
    Hakimi AA; Ostrovnaya I; Reva B; Schultz N; Chen YB; Gonen M; Liu H; Takeda S; Voss MH; Tickoo SK; Reuter VE; Russo P; Cheng EH; Sander C; Motzer RJ; Hsieh JJ;
    Clin Cancer Res; 2013 Jun; 19(12):3259-67. PubMed ID: 23620406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC.
    Xue W; Jian W; Meng Y; Wang T; Cai L; Yu Y; Yu Y; Xia Z; Zhang C
    Cell Death Dis; 2023 Aug; 14(8):539. PubMed ID: 37604811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Chiang YC; Park IY; Terzo EA; Tripathi DN; Mason FM; Fahey CC; Karki M; Shuster CB; Sohn BH; Chowdhury P; Powell RT; Ohi R; Tsai YS; de Cubas AA; Khan A; Davis IJ; Strahl BD; Parker JS; Dere R; Walker CL; Rathmell WK
    Cancer Res; 2018 Jun; 78(12):3135-3146. PubMed ID: 29724720
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
    Ibragimova I; Maradeo ME; Dulaimi E; Cairns P
    Epigenetics; 2013 May; 8(5):486-93. PubMed ID: 23644518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Decreased Expression of SETD2 Predicts Unfavorable Prognosis in Patients With Nonmetastatic Clear-Cell Renal Cell Carcinoma.
    Liu W; Fu Q; An H; Chang Y; Zhang W; Zhu Y; Xu L; Xu J
    Medicine (Baltimore); 2015 Nov; 94(45):e2004. PubMed ID: 26559293
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High selectivity of PI3Kβ inhibitors in SETD2-mutated renal clear cell carcinoma.
    Wang J; Wen J; Yi R; Liu F; Zhou J; Liu G; Li Q; Yang Z; Su X
    J BUON; 2015; 20(5):1267-75. PubMed ID: 26537074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-β-independent manner.
    Wang T; Wagner RT; Hlady RA; Pan X; Zhao X; Kim S; Wang L; Lee JH; Luo H; Castle EP; Lake DF; Ho TH; Robertson KD
    Mol Oncol; 2024 Jan; 18(1):44-61. PubMed ID: 37418588
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Loss of MLH1 confers resistance to PI3Kβ inhibitors in renal clear cell carcinoma with SETD2 mutation.
    Feng C; Ding G; Jiang H; Ding Q; Wen H
    Tumour Biol; 2015 May; 36(5):3457-64. PubMed ID: 25528216
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The roles of chromatin-remodelers and epigenetic modifiers in kidney cancer.
    Liao L; Testa JR; Yang H
    Cancer Genet; 2015 May; 208(5):206-14. PubMed ID: 25873528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of SETD2 Induces a Metabolic Switch in Renal Cell Carcinoma Cell Lines toward Enhanced Oxidative Phosphorylation.
    Liu J; Hanavan PD; Kras K; Ruiz YW; Castle EP; Lake DF; Chen X; O'Brien D; Luo H; Robertson KD; Gu H; Ho TH
    J Proteome Res; 2019 Jan; 18(1):331-340. PubMed ID: 30406665
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.